Calendario›TRAW›rigosertib

rigosertib

Safety and Efficacy of 72-hour and 120-hour Infusion of Rigosertib in Acute Myeloid Leukemia (AML) and Acute Lymphoid Leukemia (ALL)

Ensayo de Traws Pharma, Inc. en Acute Myelocytic Leukemia · Acute Lymphocytic Leukemia · Myeloproliferative Disease · Chronic Myeloid Leukemia (del registro, en inglés).

Fase

Fase 1/2

Estado

Completado

Participantes

30

previstos

Centros

1

Fin del objetivo primario

dic 2013

fecha real

Qué significa cada fase y cada estado.

Estudio de intervención, de un solo grupo, abierto. Comenzó en jul 2010.

Qué mide

Dose Limiting Toxicity (DLT) (del registro, en inglés) (hasta 8 meses)

Cómo lo describe el promotor

En el documentoEn inglés, del registroFor patients with leukemia who have not responded to or have progressed after an initial response to standard therapy, therapeutic options are limited. Although responses to standard regimens do occur, durable remissions are achieved infrequently and current regimens are not curative in the majority of patients. Identification of active agents in patients with relapsed Acute Myeloid Leukemia (AML) ultimately affords the potential for use upfront as a component of induction regimens that may translate to improved outcome. Therefore, development of new agents is of critical importance. This study will look at a new, investigational agent, ON 01910.Na, to determine if it has the potential to help Patients with AML and Acute Lymphocytic Leukemia (ALL) and transformed Myeloproliferative Neoplasms.

Más ensayos de TRAW

Todos los de TRAW, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT01167166), actualizada en jun 2017.